trending Market Intelligence /marketintelligence/en/news-insights/trending/JNYj26WULFeNxjAV4apH9Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ocular Therapeutix resubmits application to FDA for ocular pain drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ocular Therapeutix resubmits application to FDA for ocular pain drug

Ocular Therapeutix Inc. resubmitted a new drug application to the U.S. FDA seeking approval of Dextenza for the treatment of ocular pain after ophthalmic surgery.

The agency declined to approve the drug in July 2016 due to deficiencies in manufacturing process and controls.

Ocular expects to receive an indication of the scope and timing of the FDA's review of the resubmission within about 30 days. It believes that the FDA review period of the resubmission will be up to two months if a class 1 designation is received and up to six months if a class 2 designation is received.

The designation depends on whether an FDA re-inspection of the Ocular manufacturing facility will be a condition of the approval of the application.